2021 CMSC Annual Meeting

Tag: (4)Department of Neurology

Poster-Quality of Life and Outcomes

The Relationship between Illness Intrusiveness and Walking in Persons with Multiple Sclerosis

Background: Walking impairment is one of the hallmark symptoms of persons with multiple sclerosis (PwMS) and affects activities of daily...

Read More

Poster-Quality of Life and Outcomes

Perceived Health Related Quality of Life and Healthcare Resource Utilization in Persons with Multiple Sclerosis with and without Vascular Comorbidity

Background: Vascular comorbidities are prevalent in the multiple sclerosis (MS) population and can contribute to adverse health outcomes in...

Read More

Poster-Imaging

Trajectories of the Frontal Lobe Structural Changes in Relation to Retrospective and Prospective Memory in Persons with Multiple Sclerosis

Background: Sophisticated cognitive and intellectual abilities are known to be attributed to the highly convoluted gyrencephalic brain in...

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Disease-modifying Therapy

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More

Poster-Disease-modifying Therapy

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More

Poster-Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More